Palpitations in a 43-year-old man

SS Mushahwar, PA Mullins

A 43-year-old man presented to the Accident and Emergency department with sudden onset of palpitations associated with chest dullness, dizziness, and diaphoresis. On examination, the patient was haemodynamically stable, with normal heart sounds and no murmurs. The admission 12-lead electrocardiogram (ECG) is shown in figure 1 below.

Figure 1  Admission 12-lead ECG

Questions

1. What is the underlying rhythm?
2. What is the diagnosis?
3. What treatment options are available in the acute phase?
4. What is the long-term strategy in treating this condition?
Answers

QUESTION 1 UNDERLYING RHYTHM
Atrial fibrillation with pre-excited complexes. The absence of any distinct p-wave activity and the irregularity of the wide QRS complexes supports the diagnosis of atrial fibrillation. The QRS complexes, in any one lead, have a similar morphology.

QUESTION 2 DIAGNOSIS
Wolff–Parkinson–White syndrome. On restoration of sinus rhythm, the resting 12-lead ECG (figure 2) reveals a short PR interval followed by the delta wave, representing pre-excitation of ventricular tissue prior to normal conduction and depolarisation through the AV node and His bundle. Note that the delta wave is noticeable in some, but not all the leads of the standard 12-lead ECG.

QUESTION 3 TREATMENT OPTIONS
Acute treatment of this dysrhythmia depends on the clinical state of the patient, which in turn depends on the rate and resultant cardiac output.

Haemodynamically stable
After assessment of the cardiac status and routine blood tests, the treatment is aimed at controlling the ventricular rate and restoring sinus rhythm.

Controlling ventricular rate
This is achieved by various anti-arrhythmic drugs, which either block conduction down the accessory pathway (AP) or prolong the refractory period of the AP. The various drugs available are listed in the table. It is imperative to avoid anti-arrhythmic drugs that 'block' AV node conduction (eg, digoxin, calcium channel blockers, and beta-blockers) in this situation as the rapid ventricular response may degenerate into ventricular fibrillation. It is generally good practice to avoid these drugs in all broad-complex tachycardias, especially in the acute setting. Fortunately, adenosine has been used safely in this dysrhythmia, due to its short half-life (seconds).

Restoring sinus rhythm
This can be achieved either using drugs (chemical cardioversion) or synchronised direct current cardioversion. Fortunately, of the anti-arrhythmics used to achieve cardioversion, the majority are effective in controlling the ventricular rate by a direct influence on the accessory pathway (table).

Concurrent intravenous heparin therapy is recommended while the patient remains in the irregular tachycardia. The likelihood of intracardiac thrombosis increases with the duration of the dysrhythmia, due to impaired atrial contractility. It has been noted that 'atrial stunning' following successful direct current cardioversion can occur and, therefore favour thrombosis due to relative stasis in the left atrium and its appendage.

This gentleman was commenced on intravenous heparin, prior to synchronised DC cardioversion, which was successful at 50 Joules.

Haemodynamically unstable (with impending circulatory collapse)
This requires urgent intervention which is best achieved by DC cardioversion.

QUESTION 4 LONG-TERM STRATEGY
Having 'shocked' this gentleman electrically, one will have to 'shock' him mentally with the diagnosis of Wolff–Parkinson–White syndrome and its inherent risks. The main concern is the small but significant risk of sudden death. In the case of this patient, he is at risk of a future episode of atrial fibrillation inducing ventricular fibrillation, especially as the shortest RR interval on the admission ECG is measured at 180 ms. (This figure is significant. See discussion.)

The long term management of this patient’s condition consists of the following:

Education and explanation
This is essential to ensure co-operation and compliance. Explanation of the serious nature of his condition is best dealt by a knowledgeable physician, to allay his fears, and avoid any further shocks!

Anti-arrhythmic therapy
This is essential to prolong the conduction through the accessory pathway, hence reducing the risk of a life-threatening arrhythmia, while the patient awaits definitive therapy.

Electrophysiologic studies and ablation
The definitive treatment in this case is the localisation of the accessory pathway(s). Once this is done, ablation of the pathway can be performed, usually using radiofrequency energy

---

Table

<table>
<thead>
<tr>
<th>Directed at accessory pathway</th>
<th>Directed at atrial stability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flecainide (class Ic)</td>
<td>Flecainide</td>
</tr>
<tr>
<td>Sotalol (class II and III, at higher doses)</td>
<td>Sotalol</td>
</tr>
<tr>
<td>Propafenone (class Ic)</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>Amiodarone (class III)</td>
<td>Propafenone (not as good as the rest)</td>
</tr>
<tr>
<td>Quinidine*</td>
<td></td>
</tr>
<tr>
<td>Procainamide*</td>
<td></td>
</tr>
<tr>
<td>Disopyramide*</td>
<td></td>
</tr>
</tbody>
</table>

* Not very effective, especially in patients with ‘fast’ pathways
Palpitations in a 43-year-old man

delivered by special catheters. Once successfully ablated, the patient does not require anti-arrhythmic therapy.

Discussion

The Wolff–Parkinson–White syndrome was initially described in 1950.1 At the time, it was noted that several young healthy individuals had short PR intervals with left bundle branch block. It was later on that the abnormal QRS morphology was attributed to pre-excitation of ventricular tissue. This pre-excitation on the ECG was termed the delta wave.

Wolff–Parkinson–White syndrome results from the congenital presence of impulse-conducting fascicles (Kent bundles), otherwise known as accessory pathways. These fascicles connect the atria and ventricles across the annulus fibrosis. These connections can occur anywhere in this fibrous ‘divide’ and hence can give rise to different QRS morphologies and patterns of pre-excitation.23 An individual may have several accessory pathways. On occasions, the fascicles are not a discrete band, but instead exist as a mesh of fibres. Conduction through the fascicles may occur antegrade (atria to ventricle), retrogradely (ventricle to atria), or in both directions. The pattern of conduction is important, as this would dictate the types of dysrhythmias occurring (see box and figures 3 and 4) and the appropriate drug therapy.

PREVALENCE

Wolff–Parkinson–White syndrome is not an uncommon disorder. The ‘prevalence’ of pre-excitation in the general population is estimated at 0.1% to 0.3%.4 Wolff–Parkinson–White syndrome accounts for 20% of cases of paroxysmal supraventricular tachycardia. Patients may be asymptomatic, but the majority present with symptoms ranging from ‘simple’ palpitations to sudden death (see box).

INVESTIGATION

As this condition is associated with sudden death,9 there is a need to investigate this condition with a sense of urgency, especially those at risk. Ideally all patients should be considered for electrophysiologic studies, but realistically the demand that this would generate would be enormous and, as yet, not cost effective. It is generally accepted that asymptomatic patients should not be investigated, as the risk of sudden death is extremely low. In the case of symptomatic patients, it is important to try to identify those at risk of sudden death.4 Therefore, numerous groups have tried to profile those at risk patients with Wolff–Parkinson–White syndrome (see box). It is generally accepted that patients with a previous history of syncope, recurrent atrial fibrillation, short pre-excited RR intervals dur-

![Schematic diagram of possible tachycardias associated with Wolff–Parkinson–White syndrome.](http://pmj.bmj.com/)

**Figure 3**

Orthodromic tachycardia

Accessory pathway

Anodromic tachycardia

![Schematic diagram of atrial fibrillation and accessory pathway.](http://pmj.bmj.com/)

**Figure 4**

Atrial fibrillation

Orthodromic tachycardia

Atrium

AV node

His bundle

Ventricle

- orthodromic tachycardia (re-entrant circuit with antegrade ("usual") AV node conduction)
- antidromic tachycardia (circuit with retrograde AV node conduction)
- atrio-ventricular reciprocating tachycardia (usually in the presence of multiple pathways)
- atrial fibrillation (? predisposition due to micro-reentry circuits)

**Wolff–Parkinson–White syndrome: associated tachycardias**

- intermittent palpitations
- chest discomfort
- dyspnoea (sudden)
- dizziness
- pre-syncope
- syncope
- sudden death

**Wolff–Parkinson–White syndrome: attributable symptoms**
Mushahwar, Mullins

**Wolf–Parkinson–White syndrome: risk factors for sudden death**

- age
- history of syncope
- previous episodes of atrial fibrillation
- antegrade AV conduction with an effective refractory period of \(<230\) ms*
- atrial vulnerability (propensity to develop atrial fibrillation)
- presence of multiple pathways
- family occurrence (not hereditary)
- associated coronary artery disease

*This figure varies from centre to centre.

ing atrial fibrillation \(<230\) ms), or fast conducting accessory pathways, should be referred for electrophysiologic studies and pathway ablation. Electrophysiologic studies enable the cardiologist to locate the accessory pathway and look for other pathways that may be concealed. Once this information is available, then ablation can be considered. Other patients that should be considered for electrophysiologic studies and pathway ablation are those with persistent symptoms despite adequate anti-arrhythmic therapy and those with drug-related side-effects.

**MANAGEMENT**

The management of symptomatic patients with Wolf–Parkinson–White syndrome inadvertently varies from centre to centre, depending on resources and local expertise in electrophysiology. Drug therapy with various anti-arrhythmics is essential to reduce episodes of tachycardia. The ideal agents are those that prolong the conduction time and/or increase the refractory period of the part of the circuit used in sustaining the tachycardia. Therefore, drugs can be directed at the accessory pathway or the AV node (figure 3). Blocking conduction through the AV node, using digoxin, calcium channel blockers, or beta-blockers, is a possible strategy only when the tachycardias that can be induced spontaneously or during electrophysiologic studies incorporate the accessory pathway as the retrograde limb (orthodromic AV reciprocating tachycardia). Otherwise, such a strategy can be lethal, especially in the presence of atrial fibrillation. Hence, the decision to use AV ‘blocking’ drugs should only be made by experienced physicians, usually with the benefit of recent electrophysiological data.

**DRUG THERAPY**

Prolonging the conduction time through the accessory pathway is possible using any of a multitude of anti-arrhythmics (table). The ideal anti-arrhythmic would also have prophylactic properties against the recurrence of atrial fibrillation, as this is thought to be the initiating arrhythmia that precipitates ventricular fibrillation and sudden death. The mechanism for atrial fibrillation in Wolf–Parkinson–White syndrome is poorly understood, but it is debated that the presence of an accessory pathway may support micro-reentry circuits, which in turn would increase the chances of recurrence of atrial fibrillation.7 Currently the effective drugs available are sotalol, flecainide, propafenone, and amiodarone. These drugs prolong the refractory periods of the accessory pathways, especially those at high risk, but this effect can be reversed by excessive circulating catecholamines and during exercise. Again this stresses the need for further investigation and intervention, despite apparent ‘cure’ of symptoms with medication.

**SURGICAL ABLATIONS**

The curative procedure for Wolf–Parkinson–White syndrome is accessory pathway ablation. Ablation can be performed using various methods. Surgical ablation was initially performed in the 1960s. At the time this offered the first chance of cure, but was associated with significant mortality and morbidity. Despite considerable improvement in surgical ablation techniques, it is now only considered when a concomitant cardiac operation is necessary, catheter ablation has been unsuccessful, or access to the accessory pathway is technically difficult.

**CATHETER ABLATION**

The advent of catheter ablation has revolutionised the treatment of symptomatic Wolf–Parkinson–White. Initially, ablation was performed by delivering an high energy direct current shock between a catheter, placed close to the pathway, and a reference electrode. This essentially created excessive tissue damage and as a result this method is associated with numerous rhythm abnormalities. The technique has improved, but the need for general anaesthesia to relieve patient discomfort is a considerable disadvantage. More recently (1987) radiofrequency energy has been utilised with considerable success. The method utilises low energy to induce damage through transference of heat. The success rate is extremely high \((>95\%\)\), especially in experienced centres which adopt strict training programmes.8 Nowadays, patients can undergo an electrophysiological study followed by radiofrequency ablation in the same session. The various complications associated with radiofrequency ablation are listed in the box. Recurrence of the pathway is well recognised.

**Wolf–Parkinson–White syndrome: complications of radiofrequency ablation of accessory pathways**

- local vascular problems \((1.0\%)\)
- chest pain \((0.8\%)\)
- tachycardia \((0.6\%)\)
- thromboembolic \((0.5\%)\)
- aortic valve perforation \((0.4\%)\)
- pericarditis \((0.3\%)\)
- atrioventricular block \((0.3\%)\)
- pneumothorax \((0.1\%)\)
- coronary artery occlusion \((0.1\%)\)
(<5%). This is mainly due to the arrangement of the accessory bundle, which may exist as a diffuse mesh of fibres. These fibres may be stunned during radiofrequency ablation, and later on may recover. Infrequently radiofrequency ablation is not possible due to the position of the accessory bundle, surgical ablation is to be considered.

Conclusion

The Wolff–Parkinson–White syndrome is a relatively common and curable condition. As it is associated with sudden death in a minority of patients, all symptomatic patients require investigation and treatment based on various characteristics of the accessory pathway and the symptomatology. The advent of accessory pathway ablation has made freedom from a lifetime of medication a reality, especially with the introduction of radiofrequency catheter ablation. The success and low complication rates associated with radiofrequency ablation should encourage physicians to refer their patients for consideration of accessory pathway ablation, as this currently offers the ideal cure.

Final diagnosis
Wolff–Parkinson–White syndrome

Keywords: atrial fibrillation, Wolff–Parkinson–White syndrome, cardioversion


Palpitations in a 43-year-old man.

S. S. Mushahwar and P. A. Mullins

doi: 10.1136/pgmj.71.833.181

Updated information and services can be found at:
http://pmj.bmj.com/content/71/833/181.citation

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/